Summit Therapeutics (LSE:SUMM) Change In Payables And Accrued Expense : £3.18 Mil (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Summit Therapeutics Change In Payables And Accrued Expense?

Summit Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was £1.70 Mil. It means Summit Therapeutics's Accounts Payable & Accrued Expense increased by £1.70 Mil from Dec. 2023 to Mar. 2024 .

Summit Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was £-0.28 Mil. It means Summit Therapeutics's Accounts Payable & Accrued Expense declined by £0.28 Mil from Dec. 2022 to Dec. 2023 .

Summit Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Summit Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Change In Payables And Accrued Expense Chart

Summit Therapeutics Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.10

0.26

4.90

1.86

-0.28

Summit Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-1.81	-5.43	1.71	5.21	1.70

Summit Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £3.18 Mil.

Summit Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics (LSE:SUMM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

SMMT:USA

Address

2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025

Website

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics (LSE:SUMM) Headlines

No Headlines